Orig Stone Biotech

Orig Stone is a biotechnology company based in Suzhou, China, specializing in the development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary platform to design small molecule degraders, including PROTACs, aimed at addressing high-value targets in oncology that are often considered undruggable by traditional inhibitors. Their current pipeline focuses on hormone-driven cancers such as breast and prostate cancer, as well as hematological malignancies. By focusing on the degradation of pathogenic proteins rather than simple inhibition, Orig Stone aims to overcome resistance mechanisms and provide more durable clinical outcomes for patients with advanced cancers.